Using a blood test to guide radiation after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a simple blood test (ctDNA) can help doctors decide if you need radiation therapy after lung cancer surgery. The goal is to tailor your treatment to your individual risk, possibly avoiding extra radiation if you don't need it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have non-small cell lung cancer (NSCLC) at stage II or III.
- You have had surgery to remove the lung tumor.
- You are generally well enough to do daily activities without help (ECOG score 0 or 1).
- You do not have another active cancer (other than this lung cancer).
- You are willing and able to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This trial tests whether using a blood test to detect tiny amounts of cancer DNA after standard chemoradiation can help decide if extra chemotherapy and immunotherapy is right for you. It aims to improve outcomes for people with stage 3 lung cancer that can't be removed by surgery.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.